| 9:30 AM-11:00 AM |
Applying the Science Behind HDL and Cardiovascular Risk into the Primary Care Practice
Learning Objectives:
- Determine the most appropriate risk stratification techniques and screening procedures to identify patients thought to be at risk for CHD, including those with low HDL.
- Examine the epidemiology of HDL, assess the various functions of HDL, including its metabolism and molecular dynamics, and integrate the appropriate drug therapy to modulate and manage HDL, to decrease cardiovascular risk and overall atherosclerosis development.
- Evaluate the safety and efficacy of emerging therapies thought to improve HDL quality and quantity to be knowledgeable on therapeutics that may reduce residual cardiovascular risk.
Michael H. Davidson, MD, FACC, FACP
( Read Bio)
, Clinical Professor,
Director of Preventive Cardiology,
University of Chicago Pritzker School of Medicine,
Chicago, IL Alan Brown, MD, FACC, FNLA , Interventional Cardiologist,
Midwest Heart Specialists,
Naperville, IL, , Medical Director,
Midwest Heart Disease Prevention Center,
Naperville, IL, , Clinical Associate Professor of Medicine,
Stritch School of Medicine,
Loyola University,
Chicago, IL
Carl E Orringer, MD, FACC, FNLA , Herrington-McLaughlin Chair in Preventive Cardiovascular Medicine,
University Hospitals Case Medical Center,
Cleveland, OH, , Associate Professor of Medicine,
Case Western Reserve University School of Medicine,
Cleveland, OH
|
| 1:00 PM-2:15 PM |
Benign Prostatic Hyperplasia - Optimizing Management in the Primary Care Setting
Learning Objectives:
- Conduct an initial and ongoing assessment of patients with BPH, addressing LUTS, coexisting disorders, patient quality of life and function
- Evaluate the risk of BPH disease progression and complications
- Teach patients with BPH-LUTS practical self-management approaches and behavioral modifications to slow disease progression
- Evaluate the clinical profiles and utility of 5-a reductase inhibitors (5-ARIs), a-1 adrenergic receptor blockers, and phosphodiesterase-5 (PDE-5) inhibitors for patients with BPH-LUTS with and without ED
- Tailor monotherapy and multidrug regimens for patients with BPH-LUTS based in part on signs and symptoms, prior medication history, ED and other common comorbidities, risk of disease progression, and patient goals
Martin M. Miner, MD
( Read Bio)
, Clinical Associate Professor of Family Medicine and Urology,
The Warren Alpert Medical School,
Brown University,
Providence, RI, , Chief of Family and Community Medicine,
Miriam Hospital,
Providence, RI Matt T Rosenberg, MD , Medical Director,
Mid-Michigan Health Centers,
Jackson, MI
|
| 2:30 PM-4:00 PM |
Insulin 101: An Introduction to Insulin Therapy in the 21st Century
Learning Objectives:
- Calculate appropriate insulin doses for initiating basal and basal-prandial insulin regimens in T2DM
- Demonstrate best practices in insulin injection and SMBG techniques to improve treatment adherence and potentially impact patient outcomes
- Apply pattern recognition to SMBG data to appropriately titrate insulin doses and adjust insulin regimens to specific patient needs
- Summarize the efficacy and safety findings from clinical trials of investigational insulins and the combination of incretin-based therapies with insulin
Davida F Kruger, MSN , APRN , BC-ADM , Certified Nurse Practitioner,
Henry Ford Health Sysrem,
Detroit, MI, Division of Endocrinology, Diabetes, Bone and Mineral Disease,
Detroit, MI
Guillermo E Umpierrez, MD, FACP , FACE , Professor of Medicine,
Division of Endocrinology and Metabolism,
Section Chief, Diabetes and Endocrinology,
Director, Grady Health System,
Emory University School of Medicine,
Atlanta, GA
|
